Ignite Creation Date:
2025-12-24 @ 6:35 PM
Ignite Modification Date:
2025-12-25 @ 4:05 PM
Study NCT ID:
NCT05907057
Status:
RECRUITING
Last Update Posted:
2025-04-11
First Post:
2023-06-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Sponsor:
Servier Affaires Médicales
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2026-01-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-15
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-08
First Submit QC Date:
None
Study First Post Date:
2023-06-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-08
Last Update Post Date:
2025-04-11
Last Update Post Date Type:
ACTUAL